<div id="readability-page-1"><p>Assenagon Asset Management S.A. cut its holdings in shares of  Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 224,128 shares of the company's stock after selling 13,870 shares during the period. Assenagon Asset Management S.A. owned 0.34% of Rhythm Pharmaceuticals worth $22,635,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</span></p></div><ul><li>7 Stocks That Will Drive the Weight Loss Drugs Market</li></ul><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in  Rhythm Pharmaceuticals by 3.6% in the 1st quarter. Rhumbline Advisers now owns 85,719 shares of the company's stock worth $4,541,000 after purchasing an additional 2,988 shares in the last quarter.  Siren L.L.C. purchased a new position in shares of  Rhythm Pharmaceuticals during the first quarter valued at about $14,701,000.  Voleon Capital Management LP purchased a new position in shares of  Rhythm Pharmaceuticals during the first quarter valued at about $732,000.  Intech Investment Management LLC lifted its holdings in  Rhythm Pharmaceuticals by 20.7% in the first quarter. Intech Investment Management LLC now owns 33,893 shares of the company's stock worth $1,795,000 after buying an additional 5,801 shares during the period.  Finally, Harbor Capital Advisors Inc. boosted its position in  Rhythm Pharmaceuticals by 12.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 86,546 shares of the company's stock valued at $5,469,000 after acquiring an additional 9,249 shares in the last quarter. </p><h2>Rhythm Pharmaceuticals Price Performance</h2><p>RYTM stock opened at $112.14 on Friday. Rhythm Pharmaceuticals, Inc. has a 1-year low of $45.90 and a 1-year high of $122.20. The business has a fifty day moving average price of $106.54 and a 200-day moving average price of $93.80. The stock has a market capitalization of $7.48 billion, a P/E ratio of -36.17 and a beta of 1.96. </p><ul><li> 2 biotechs with promising weight-loss drugs coming</li></ul><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.The business had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.71 million.  As a group, analysts anticipate that  Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><p>In other news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares in the company, valued at $2,310,354. The trade was a 13.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Joseph Shulman sold 9,748 shares of the stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the transaction, the insider owned 8,509 shares in the company, valued at approximately $980,577.16. This trade represents a 53.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,350 shares of company stock valued at $3,436,340 over the last quarter. Company insiders own  6.10% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>A number of research firms have recently commented on RYTM. Guggenheim raised their target price on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday. Cowen  reissued a &#34;buy&#34; rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. UBS Group  reaffirmed a &#34;buy&#34; rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday. JMP Securities increased their price target on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Thursday, September 25th. Finally, Oppenheimer cut shares of Rhythm Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Wednesday, November 5th. One research analyst  has rated the stock with a Strong Buy rating, sixteen have issued  a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $125.60.</p><p><b>Read Our Latest Report on RYTM</b></p><h2>Rhythm Pharmaceuticals Profile</h2> (Free Report)<p>Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.  </p><p>The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Rhythm Pharmaceuticals</li><li>Dividend Payout Ratio Calculator</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>3 Warren Buffett Stocks to Buy Now</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?</h2><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p><p>While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RYTM

<p>Assenagon Asset Management S.A. reduced its stake in Rhythm Pharmaceuticals by 5.8%, selling 13,870 shares. Rhythm Pharmaceuticals' stock opened at $112.14, with a 1-year low of $45.90 and high of $122.20. Analysts have mixed ratings, with Guggenheim raising the target price to $140 and Oppenheimer downgrading to 'market perform.' Insiders sold 30,350 shares valued at $3,436,340 last quarter.</p>

Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM